Q PRESENTATION November 28, 2017 Per Walday, CEO Ronny Skuggedal, CFO

Transcription

1 Q PRESENTATION November 28, 2017 Per Walday, CEO Ronny Skuggedal, CFO 1

2 PCI BIOTECH Important notice and disclaimer This presentation may contain certain forward-looking statements and forecasts based on uncertainty, since they relate to events and depend on circumstances that will occur in the future and which, by their nature, will have an impact on PCI Biotech s business, financial condition and results of operations. The terms anticipates, assumes, believes, can, could, estimates, expects, forecasts, intends, may, might, plans, should, projects, programmes, will, would or, in each case, their negative, or other variations or comparable terminology are used to identify forward-looking statement. There are a number of factors that could cause actual results and developments to differ materially from those expressed or implied in a forward-looking statement or affect the extent to which a particular projection is realised. Factors that could cause these differences include, but are not limited to, implementation of PCI Biotech s strategy and its ability to further grow, risks associated with the development and/or approval of PCI Biotech s products candidates, ongoing clinical trials and expected trial results, the ability to commercialise fimaporfin (Amphinex ), technology changes and new products in PCI Biotech s potential market and industry, the ability to develop new products and enhance existing products, the impact of competition, changes in general economy and industry conditions and legislative, regulatory and political factors. No assurance can be given that such expectations will prove to have been correct. PCI Biotech disclaims any obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. The reservation is also made that inaccuracies or mistakes may occur in this information given about current status of the Company or its business. Any reliance on the information is at the risk of the reader, and PCI Biotech disclaims any and all liability in this respect. 2

3 HIGHLIGHTS Q fimachem Granted US Orphan Drug Designation Phase I extension study progressing according to plan fimavacc Promising interim clinical results from Phase I suggesting enhancement of several parameters of importance for vaccination Expanding the clinical Phase I study to identify optimal dosing fimanac Extension of the top-10 pharma collaboration Corporate Strengthened management team further by the appointment of Dr Hans Olivecrona as Chief Medical Officer 3

4 PCI BIOTECH AT A GLANCE Unlocking the potential of innovative medicines A listed (PCIB:NO) cancer-focused biotech company Photochemical internalisation ( PCI ) technology, originating from the Norwegian Radium Hospital Programme Indications / Therapeutics Preclinical Phase I Phase II Status fimachem fimavacc Bile duct cancer / gemcitabine Therapeutic cancer vaccines Phase I extension to evaluate safety of repeated treatment in the orphan indication bile duct cancer Phase I study in healthy volunteers One active R&D collaboration fimanac Nucleic acid therapeutics Four active R&D collaborations An oncology focused company with three well differentiated assets 4

5 PCI TECHNOLOGY Enabling drugs to reach intracellular therapeutic targets PCI the solution to a key challenge for several modalities 5

6 THE SOLUTION TO A KEY CHALLENGE Three well-defined development programmes fimachem fimavacc fimanac PCI may enhance approximately 20% of relevant approved chemotherapies Total sales of cancer vaccines estimated to reach $7,5bn in 2022** Main HURDLE IS DELIVERY into cells First-in-man study published in Lancet Oncology* Promising tumour responses in Phase I in inoperable extrahepatic bile duct cancer Incidence close to 15,000 (Eur.+US), with 3,000 assumed eligible for fimachem Possible upside in distal and metastatic disease, and in Asia Orphan disease with high price potential Expected market growth largely driven by therapeutic vaccine combinations with checkpoint inhibitors Aim is to out-license the technology on non-/semi-exclusive basis Opportunity to develop own therapeutic vaccination products Estimated sales of $18bn in 2030*** (RNAi alone) Opportunistic collaborative approach Aim is to out-license the technology on non-/semi-exclusive basis * Lancet Oncology (2016) 17(9): p ** GBI Research (2016) Global Cancer Vaccines Market to 2022 *** Research and Markets (2015) RNAi therapeutics market 6

7 PCI TECHNOLOGY fimachem mode of action Cancer cell Chemotherapeutics Endocytosis chemotherapeutic E.g. Release into cytosol Cytotoxic antibiotics Antimetabolites Antimicrotubule agents Lysosomal Breakdown DNA intercalation; free radical formation; etc. DNA /RNA synthesis inhibition; DNA damage Cell cycle arrest 7

8 BILE DUCT CANCER Excellent fit between medical need and fimachem Orphan indication, yearly incidence rate of 1-2 per 100,000 in the western world higher in Asia Five-year survival rate of less than 5% and almost 0% when inoperable Average survival inoperable: 12 months Current management Surgery Only potentially curative treatment Less than ⅓ are resectable at presentation Stenting Endoscopic stenting for palliative biliary drainage Chemotherapy No approved chemotherapy Recommended: gemcitabine and cisplatin Enhancing the active and recommended chemotherapy Easy illumination through standard endoscopic methods Boosting chemotherapy effect where it is most needed Inducing immunogenic tumour cell death Combination therapy with gemcitabine and cisplatin is recommended Gemcitabine is significantly enhanced by fimachem Conjoining localised with systemic therapy Patients are treated with endoscopic methods (ERCP) for diagnosis and stenting Optic fibre and illumination easily included in the ERCP procedure Tumours tend to block the bile duct Liver function is often affected Biliary drainage is key for patient treatment and survival Preclinical and clinical data supports the notion of potential abscopal effects with fimachem May be ideal for combination with checkpoint inhibitors 8

9 Percentage change in overall tumour size BILE DUCT CANCER CLINICAL PHASE I/II STUDY Encouraging early signs of efficacy in Phase I Interim average overall survival (OS) of all 16 patients in Phase I was 16.5 months per November 2017, with 25% of the patients still being alive. Median OS ended at 14.4 months. Best Overall Response (all radiologically evaluable patients) 100% 80% 60% 40% 20% 0% -20% -40% Cohort 1 (n=2) Cohort 2 (n=2) Cohort 3 (n=3) Cohort 4 (n=4) -60% -80% -100% 9

10 BILE DUCT CANCER PHASE I EXTENSION STUDY Repeating the fimachem treatment with the aim to further enhance efficacy Exploring safety of repeating the fimachem treatment in an extension to Phase I, which may allow for repeated treatment in a potential pivotal Phase II study The study is progressing according to plan and done in parallel with other preparations for the next phase 10

11 INOPERABLE EXTRAHEPATIC BILE DUCT CANCER Status and strategy going forward Orphan designation Granted in both the US and EU, recognising the medical need and potential therapeutic benefits Phase I completed with good tolerability and promising early signs of efficacy Tumour shrinkage in almost all radiologically evaluable patients Interim average overall survival (OS) of 16.5 months with 25% of patients still alive; median OS ended at 14.4 months Exploring safety of repeated treatment as a Phase I extension First patient included in August 2017 study progressing according to plan Regulatory interactions with authorities to determine fastest way to market Interactions continued during Q3 with productive discussions to establish a strong and viable development strategy Engaging US key opinion leaders (KOL s) Engaging US KOL s and conducted a clinical advisory board meeting to advise on Phase II design 11

12 PCI TECHNOLOGY fimavacc mode of action Dendritic cell Vaccine Endocytosis MHC I MHC II MHC Class I MHC Class II proteasomes vaccine antigen Generate more disease specific cytotoxic T-cells Attack cancer and virusinfected cells more efficiently Antibodies and helper T-cells 12

13 PROGRESSING CLINICAL TRANSLATION Phase I study in healthy volunteers Overall objective: Determine the safety, tolerability and immune response of fimavacc in healthy subjects Study consists of three parts: 1. Tolerability of intradermal fimaporfin, adjuvant and light (without vaccine) 2. fimavacc vaccination: dose finding (fimaporfin and light) and cohort expansion 3. Optimisation of the fimavacc regimen Status: More than 70 subjects have so far been included Part 1 is completed Part 2 is ongoing Initial data suggest overall T-cell enhancement at tolerable doses, as well as early responses and high response rates Notably, best responses at the lowest fimaporfin dose tested study will be expanded to include lower doses Part 3 not yet started Optimisation of timing of light Expected completion: 2H

14 PCI TECHNOLOGY fimanac mode of action Target cell Nucleic Acid Therapeutics Endocytosis nucleic acid therapeutic Knockdown of gene expression Release into cytosol sirna mirna mrna DNA Therapeutic protein production CRISPR Repair of genetic defects Lysosomal Breakdown 14

15 RESEARCH COLLABORATIONS Five active collaborations within nucleic acid therapeutics and vaccination fimanac RXi Pharmaceuticals Initiated Q Listed on Nasdaq, developing innovative therapeutic sirna Expanded to immuno-oncology following RXi s MirImmune acquisition Top-10 large pharma Initiated Q A global leader in nucleic acid therapeutics Expanded to include in vivo studies current agreement to end of 2017, but may be further extended BioNTech Initiated Q German biotech company developing individualised cancer immunotherapies Clinical programmes in melanoma, head & neck, breast, ovarian and pancreatic cancer fimavacc etherna Initiated Q A global leader in mrna-based immunotherapies Evaluate synergistic effects between companies technologies Ultimovacs Initiated Q Norwegian immunotherapy company Therapeutic cancer vaccine against human telomerase Research collaborations aim to evaluate synergies between the fima platform and partner technologies, with the potential for further partnerships 15

16 FINANCE Key financial figures (In NOK 1,000) 2017 Q Q YTD 2016 YTD Operating results Cash & cash equivalents SkatteFUNN grant of NOK 5.9 million to be received in Q4 Cash position to reach key milestones: Initiation of fimachem Phase II Completion of fimavacc Phase I 16

17 GOOD PROGRESS IN ALLAREAS YTD 2017 fimachem fimachem fimavacc fimavacc fimanac Finance Corporate Granted orphan designation in the US Initiated patient enrolment in the extension of Phase I Tolerability of the vaccination technology established Promising initial immune response results Preclinical research collaborations entering new stages Secured financing to reach key milestones Strengthened the organisation with Dr Olivecrona as CMO 17

18 KEY MILESTONES ANTICIPATED Through H H H H 2018 fimachem fimachem fimachem fimavacc Regulatory clarity on fastest way to market Safety read-out of Phase I extension Initiation of Phase II Phase I in healthy volunteers completed 18

19 PCI BIOTECH Summary and outlook fimachem Granted orphan drug designation in the US Strong tumour response and encouraging survival data Phase I extension study progressing according to plan Productive regulatory interactions approaching outcome Engaged US KOL s and discussed clinical design, preparing for Phase II fimavacc Tolerability established Promising initial results with several features of importance for vaccination platforms Notably, best responses at lowest dose expanding dose finding to explore lower doses fimanac Top-10 pharma collaboration entered in vivo studies and extended until end of 2017 may be further extended Cash position to reach key milestones 19

20 PCI BIOTECH HOLDING ASA Enquiries CEO Per Walday Cell phone: Telephone: CFO Ronny Skuggedal Cell phone: Telephone: